XML 84 R70.htm IDEA: XBRL DOCUMENT v3.20.2
Fair Value Considerations (Details 6) - Beta
Feb. 14, 2020
Nov. 01, 2019
Cerecor, Inc. | Product Technology Rights    
Re-levered Beta [1]   1.60
Market risk premium [1]   6.00%
Small stock risk premium [1]   5.20%
Risk-free interest rate [1]   2.00%
Company specific discount [1]   25.00%
Innovus Pharmaceuticals | Patents & Trademarks    
Re-levered Beta 0.84  
Market risk premium 6.17%  
Small stock risk premium 4.99%  
Risk-free interest rate 1.89%  
Company specific discount 20.00%  
[1] Valuation performed as of November 1, 2019. As a non-recurring fair value measurement, there is no remeasurement at each reporting period unless indications exist that the fair value of the asset has been impaired. There were no indicators as of June 30, 2020 that the fair value of the Product technology rights was impaired.